| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Ozuriftamab Vedotin | HTBA-3021; CAB-ROR2; CAB-ROR2-ADC; CAB-ADC; BA-3021 | Phase 2 Clinical | Bioatla | Carcinoma, Non-Small-Cell Lung; Head and Neck Neoplasms; Melanoma; Neoplasm Metastasis; Ovarian Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms | Details |